

## Manuscript Details

<b>Manuscript number</b>	GHP_2019_194
<b>Title</b>	The Case Against Coprescribing Opioids and Antidepressants
<b>Article type</b>	Letter to the Editor
<b>Corresponding Author</b>	Golo Kronenberg
<b>Order of Authors</b>	Golo Kronenberg, Karen Gertz

## Submission Files Included in this PDF

### File Name [File Type]

cover letter Kronenberg Gertz.docx [Cover Letter]

Letter to the Editor\_title page.docx [Title Page (with Author Details)]

Letter to the Editor\_General Hospital Psychiatry.docx [Manuscript (without Author Details)]

To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE Homepage, then click 'Download zip file'.



Jeff C Huffman

Editor-in-Chief

General Hospital Psychiatry

BHF Research Centre  
Glenfield Hospital  
Groby Road  
LEICESTER LE3 9QP

Golo Kronenberg  
Chair in Adult and Liaison Psychiatry  
Tel: +44 (0)116 204 4776  
Email: [gdk7@leicester.ac.uk](mailto:gdk7@leicester.ac.uk)

11 May 2019

***Submission, Kronenberg & Gertz***

***Letter to the Editor***

***The Case Against Coprescribing Opioids and Antidepressants***

*Comment on*

*O'Connell et al., Medication prescriptions in 322 motor functional neurological disorder patients in a large UK mental health service: A case control study  
Gen Hosp Psychiatry 2019;58:94-102*

Dear Dr Huffman,

Thanks again for your e-mail. I have appended for your review a revised version of our comment. We are grateful for the opportunity to resubmit the revised text.

Many thanks for your consideration.

Golo Kronenberg

## Letter to the Editor

### The Case Against Coprescribing Opioids and Antidepressants

Comment on

*Medication prescriptions in 322 motor functional neurological disorder patients in a large UK mental health service: A case control study.*

Golo Kronenberg<sup>1\*</sup>, Karen Gertz<sup>2</sup>

1. College of Life Sciences, University of Leicester, and Leicestershire Partnership National Health Service Trust, Leicester, U.K.

2. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik und Hochschulambulanz für Neurologie und Centrum für Schlaganfallforschung Berlin, Berlin, Germany.

\*Electronic address: [gdk7@leicester.ac.uk](mailto:gdk7@leicester.ac.uk) (G. Kronenberg)

We read with great interest the article by O'Connell and colleagues in *The General Hospital Psychiatry* presenting, for the first time, detailed information on pharmacotherapy in the care of motor functional neurological disorder (mFND) patients (1). The report strongly suggests that a substantial fraction of mFND patients receive antidepressants and opioids concurrently (1). We wish the authors had elaborated further and more explicitly on this point.

Based on our own experiences in neurology and psychiatry, many clinicians are not fully aware of the fact that the combination of antidepressants and opioids may precipitate serotonin toxicity (2). It is only recently that the Food and Drug Administration has issued a blanket safety communication and mandated changes to the labels of prescription opioids to warn about the risk of serotonin syndrome (3). Moreover, new research findings indicating that prodrug opioids are less effective in patients on SSRIs have yet to be absorbed into clinical practice (4) .

Considering the wide readership of *General Hospital Psychiatry* among clinicians and, in particular, junior medical staff, we think these are important points to make. Otherwise, many readers may come away from the article by O'Connell *et al.* (1) thinking that if these prescribing habits are frequently encountered at the South London and Maudsley (SLaM) NHS Foundation Trust, one of the premier psychiatric services in the world, they must surely be acceptable everywhere else.

Conflicts of interest

None.

## References

- (1) O'Connell N, Nicholson T, Blackman G, Tavener J, David AS. Medication prescriptions in 322 motor functional neurological disorder patients in a large UK mental health service: A case control study. *Gen Hosp Psychiatry* 2019; 58:94-102
- (2) Rastogi R, Swarm RA, Patel TA. Case scenario: opioid association with serotonin syndrome: implications to the practitioners. *Anesthesiology* 2011; 115:1291-8
- (3) Food and Drug Administration. Safety Announcement [3-22-2016]. <https://www.fda.gov/media/96472/download> (accessed May 11, 2019)
- (4) Parthipan A, Banerjee I, Humphreys K, Asch SM, Curtin C, Carroll I, et al. Predicting inadequate postoperative pain management in depressed patients: A machine learning approach. *PLoS One* 2019; 14(2):e0210575